Hinge Health shares surged 23% on Wednesday after the musculoskeletal-care company reported its first quarterly results since its recent listing, posting 55% year-over-year revenue growth and positive cash flow. The rally leaves the stock 52% above its IPO price. The company said uptake of its artificial-intelligence-enabled digital clinic—which combines motion-tracking technology, FDA-cleared wearables and remote clinical teams—continues to scale following the June debut. Brokerages responded by lifting their targets. Citizens JMP Securities raised its price objective to $65 from $58, Bank of America to $64 from $42 and Barclays to $62 from $51. Evercore ISI moved to $60 from $50, Needham & Co. to $59 from $47 and Morgan Stanley to $57 from $46, with each firm maintaining bullish ratings on the stock.